Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT04209959

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04209959
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04209959. Randomized; single masking; primary purpose treatment. Start 2019-01-01 (actual); primary completion 2020-01-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation
Intervention (Drug)
nifekalant
Lead sponsor
Second Affiliated Hospital of Nanchang University (class: other)

Record details

Record id
cardio:ct-nct04209959
Content hash
b720d2f14ca570de13f697e1ab7aefd4216bb0d06e4944bba947f35733c2e7f7